Experts Urge Caution as GLP-1 Drugs Show Growing Benefits Beyond Diabetes and Obesity

Newer glucagon-like peptide-1 (GLP-1) therapies such as semaglutide and tirzepatide have shown benefits extending beyond their original uses for type 2 diabetes and weight management, prompting debate among clinicians over whether the medicines could become a broadly used treatment for multiple conditions. Medical experts and clinicians say the drugs’ expanding profile is promising but caution that calling them an "everything drug" overstates the current evidence and overlooks ongoing safety, long-term effectiveness and access issues.

GLP-1 receptor agonists — most widely recognized by brand names including Ozempic and Wegovy (semaglutide) and Mounjaro and Zepbound (tirzepatide) — were developed to improve blood-sugar control and to aid weight loss. In recent months, randomized trials and observational analyses have reported benefits in other areas, including improvements in cardiovascular outcomes and markers of fatty liver and kidney disease, prompting renewed interest in broader clinical uses and additional regulatory considerations.

"I would caution against labeling any medication as an ‘everything drug,’" said Dr. Angela Fitch, co-founder and chief medical officer of knownwell, a weight-inclusive healthcare company in Boston. Fitch said GLP-1s have demonstrated important clinical promise but urged a tempered view as the medical community evaluates the breadth and durability of benefits.

Regulators have approved several GLP-1 drugs for treatment of type 2 diabetes and for weight management in people with obesity or overweight with weight-related health problems. Clinical trials and post-approval studies have since identified benefits in cardiovascular risk profiles, reductions in liver fat, and slower progression of kidney disease in some patient groups, findings that have sparked research into additional indications and broader clinical adoption.

Physicians and researchers emphasize that the evidence varies by condition and by specific agent, and that many of the reported effects emerged from trials primarily designed to test metabolic outcomes rather than those other disease endpoints. Experts say longer-term randomized trials and real-world safety monitoring are needed to determine which benefits are reliably attributable to the drugs, which patient groups are most likely to benefit and how to balance risks and costs.

Concerns also remain about side effects and suitability. Common short-term adverse effects reported in clinical studies include gastrointestinal symptoms such as nausea and diarrhea; rare but serious concerns have been raised about other potential risks that require longer follow-up to quantify. Clinicians have also warned that the popularity of GLP-1 therapies for cosmetic weight loss may lead some patients to use them without appropriate medical oversight or in combination with other treatments, complicating safety assessments.

Beyond clinical effectiveness and safety, questions about access and affordability are shaping the debate. Many patients who could potentially benefit face high out-of-pocket costs, insurance restrictions and limited supply, which clinicians say complicates equitable use and long-term adherence. Public-health experts have noted that widely promoting drug therapy without ensuring parallel investments in lifestyle interventions and systems of care could widen disparities in health outcomes.

Those who study metabolic disease stress that GLP-1s are not a substitute for comprehensive management. Behavioral interventions, dietary patterns and other lifestyle measures remain central to preventing and treating chronic conditions such as diabetes and fatty liver disease. Some clinicians caution that overreliance on pharmacotherapy may divert attention from those proven, population-level strategies.

Manufacturers and researchers continue to pursue trials testing GLP-1s for a range of conditions and combinations with other therapies. Regulators will evaluate submitted data for new indications case by case, and professional societies are updating guidelines as evidence accumulates. In the interim, clinicians interviewed by health reporters advise prescribing the drugs to patients based on current evidence, individual risk profiles and shared decision-making.

As research unfolds, advocates and clinicians say transparent communication about benefits, risks and uncertainties is essential. Accurate information and careful stewardship of prescriptions, combined with continued study of long-term outcomes and equitable access, will determine whether GLP-1 therapies become a mainstay for a wider array of medical conditions or remain targeted tools within metabolic medicine.